149 related articles for article (PubMed ID: 9808534)
1. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis.
Goss KJ; Brown PD; Matrisian LM
Int J Cancer; 1998 Nov; 78(5):629-35. PubMed ID: 9808534
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase inhibitors.
Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation.
Chavey C; Mari B; Monthouel MN; Bonnafous S; Anglard P; Van Obberghen E; Tartare-Deckert S
J Biol Chem; 2003 Apr; 278(14):11888-96. PubMed ID: 12529376
[TBL] [Abstract][Full Text] [Related]
4. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
Low JA; Johnson MD; Bone EA; Dickson RB
Clin Cancer Res; 1996 Jul; 2(7):1207-14. PubMed ID: 9816289
[TBL] [Abstract][Full Text] [Related]
5. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice.
Sledge GW; Qulali M; Goulet R; Bone EA; Fife R
J Natl Cancer Inst; 1995 Oct; 87(20):1546-50. PubMed ID: 7563189
[TBL] [Abstract][Full Text] [Related]
6. Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
Holst-Hansen C; Low JA; Stephens RW; Johnson MD; Carmeliet P; Frandsen TL; Brünner N; Dickson RB
Breast Cancer Res Treat; 2001 Aug; 68(3):225-37. PubMed ID: 11727959
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase inhibitors: a novel class of anticancer agents.
Brown PD
Adv Enzyme Regul; 1995; 35():293-301. PubMed ID: 7572350
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.
Zervos EE; Shafii AE; Rosemurgy AS
J Surg Res; 1999 Jan; 81(1):65-8. PubMed ID: 9889060
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
[TBL] [Abstract][Full Text] [Related]
10. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats.
Aparicio T; Kermorgant S; Dessirier V; Lewin MJ; Lehy T
Carcinogenesis; 1999 Aug; 20(8):1445-51. PubMed ID: 10426790
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases.
Taraboletti G; Garofalo A; Belotti D; Drudis T; Borsotti P; Scanziani E; Brown PD; Giavazzi R
J Natl Cancer Inst; 1995 Feb; 87(4):293-8. PubMed ID: 7535861
[TBL] [Abstract][Full Text] [Related]
13. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
14. High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells.
Páez Pereda M; Ledda MF; Goldberg V; Chervín A; Carrizo G; Molina H; Müller A; Renner U; Podhajcer O; Arzt E; Stalla GK
J Clin Endocrinol Metab; 2000 Jan; 85(1):263-9. PubMed ID: 10634397
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines.
Afzal S; Lalani el-N ; Foulkes WD; Boyce B; Tickle S; Cardillo MR; Baker T; Pignatelli M; Stamp GW
Lab Invest; 1996 Feb; 74(2):406-21. PubMed ID: 8780160
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts.
Noël A; Hajitou A; L'Hoir C; Maquoi E; Baramova E; Lewalle JM; Remacle A; Kebers F; Brown P; Calberg-Bacq CM; Foidart JM
Int J Cancer; 1998 Apr; 76(2):267-73. PubMed ID: 9537590
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo.
Zervos EE; Norman JG; Gower WR; Franz MG; Rosemurgy AS
J Surg Res; 1997 May; 69(2):367-71. PubMed ID: 9224409
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases of human NK cells.
Albertsson P; Kim MH; Jonges LE; Kitson RP; Kuppen PJ; Johansson BR; Nannmark U; Goldfarb RH
In Vivo; 2000; 14(1):269-76. PubMed ID: 10757086
[TBL] [Abstract][Full Text] [Related]
19. Matrilysin in early stage intestinal tumorigenesis.
Fingleton BM; Heppner Goss KJ; Crawford HC; Matrisian LM
APMIS; 1999 Jan; 107(1):102-10. PubMed ID: 10190286
[TBL] [Abstract][Full Text] [Related]
20. Batimastat. BB 94, collagenase inhibitors-1.
Drugs R D; 1999 Feb; 1(2):139-41. PubMed ID: 10566008
[No Abstract] [Full Text] [Related]
[Next] [New Search]
